Oprozomib iramate and orally bioavailable inhibitors of

and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity

Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential

InChi: InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

5%) is capable of significantly reducing the inflammatory oedema in the arachidonic acid induced ear oedema model in mice

Oprozomib iramate and orally bioavailable inhibitors ofOprozomibm, also known as ONX 0912 and PR 047 , is a n orally bioavailable proteasome inhibitor with potential antineoplastic activity. ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and